アトピー性皮膚炎治療薬市場：薬剤クラス別、投与経路別-2025-2030年の世界予測

アトピー性皮膚炎治療薬市場は、2023年に80億2,000万米ドルと評価され、2024年には85億6,000万米ドルに達すると予測され、CAGR 6.84％で成長し、2030年には127億6,000万米ドルに達すると予測されています。

アトピー性皮膚炎（AD）治療薬には、アトピー性皮膚炎の症状を管理・治療するための治療薬が含まれます。アトピー性皮膚炎は、かゆみや炎症を伴う皮膚の斑点を特徴とする慢性炎症性皮膚疾患です。これらの薬剤の必要性は、小児と成人の両方の集団に影響を及ぼすアトピー性皮膚炎の世界の有病率に起因しており、緩和を提供し、生活の質を改善する効果的な治療法の需要につながっています。適用範囲は主に局所治療薬、全身治療薬、生物学的製剤で、エンドユーザーは病院、薬局、オンライン小売業者、皮膚科クリニックなど多岐にわたる。主な成長要因としては、皮膚の健康に対する意識の高まり、ヘルスケア支出の増加、バイオテクノロジーの進歩、モノクローナル抗体やJAK阻害剤などの革新的薬剤のパイプラインの拡大などが挙げられます。最近のビジネスチャンスとしては、特異性の高い炎症経路を標的とする生物学的製剤の使用拡大や、遺伝子プロファイルに基づいて治療を調整する個別化医療の可能性が挙げられます。しかし、市場開拓には高い薬剤開発コスト、規制上のハードル、大規模な臨床試験の必要性、競合市場のダイナミクス、一部の治療に伴う副作用の可能性などが課題となっています。新たな機会を捉えるため、利害関係者は、より効果的で安全な生物製剤の開発、自然療法や代替療法の探求、AD症状のモニタリングと管理のためのデジタル治療薬の活用を推進する研究開発への投資に注力すべきです。共同研究やパートナーシップに積極的に関与することで、知識の移転や革新的なブレークスルーを促進することができます。さらに、技術革新は、より費用対効果の高い製剤を生み出し、利用しやすくすることを目指すことができます。市場の競争は激しく、研究集約型であり、科学の進歩や患者中心の需要によって常に進化していることが特徴であるため、市場で優位に立つためには機敏な戦略が必要となります。

市場力学：急速に進化するアトピー性皮膚炎治療薬市場の主要市場インサイトを公開

アトピー性皮膚炎治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • アトピー性皮膚炎の罹患率の増加
  • アトピー性皮膚炎を悪化させる食物アレルギーの有病率の増加
  • 皮膚バリアを保護する新規保湿剤、生物製剤、脂質補充外用薬の開発
• 市場抑制要因
  • 治療薬の高コスト
• 市場機会
  • 治療法に対する意識の高まり
  • 様々な発展途上国における治療へのアクセスの増加
• 市場の課題
  • 投薬に伴う副作用

ポーターのファイブフォース：アトピー性皮膚炎治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：アトピー性皮膚炎治療薬市場における外部からの影響の把握

外部マクロ環境要因は、アトピー性皮膚炎治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析アトピー性皮膚炎治療薬市場における競合情勢の把握

アトピー性皮膚炎治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスアトピー性皮膚炎治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、アトピー性皮膚炎治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨アトピー性皮膚炎治療薬市場における成功への道筋を描く

アトピー性皮膚炎治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • アトピー性皮膚炎の発症率の増加
    • 食物アレルギーの増加がアトピー性皮膚炎を悪化させている
    • 皮膚バリア保護効果のある新規保湿剤、生物製剤、脂質補給外用薬の開発
  • 抑制要因
    • 治療費の高騰
  • 機会
    • 病気の治療法の入手可能性に関する意識の高まり
    • さまざまな新興諸国で治療へのアクセスが拡大
  • 課題
    • 薬の使用に伴う副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 アトピー性皮膚炎治療薬市場薬剤クラス別

• 生物学的製剤
• カルシニューリン阻害剤
• コルチコステロイド
• ホスホジエステラーゼ4阻害剤

第7章 アトピー性皮膚炎治療薬市場：投与経路別

• 注射可能なROA
• 経口ROA
• 熱帯ROA

第8章 南北アメリカのアトピー性皮膚炎治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のアトピー性皮膚炎治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのアトピー性皮膚炎治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Biofrontera AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Galderma S.A.
• GlaxoSmithKline PLC
• LEO Pharma A/S
• Meda AB
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. ATOPIC DERMATITIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ATOPIC DERMATITIS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ATOPIC DERMATITIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ATOPIC DERMATITIS DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PHOSPHODIESTERASES 4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 23. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 38. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. POLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. POLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 103. ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Atopic Dermatitis Drugs Market was valued at USD 8.02 billion in 2023, expected to reach USD 8.56 billion in 2024, and is projected to grow at a CAGR of 6.84%, to USD 12.76 billion by 2030.

Atopic dermatitis (AD) drugs encompass therapeutic medications designed to manage and treat the symptoms of atopic dermatitis, a chronic inflammatory skin condition marked by itchy and inflamed patches of skin. The necessity for these drugs is driven by the significant prevalence of atopic dermatitis globally, which impacts both pediatric and adult populations, leading to demand for effective treatments that offer relief and improve life quality. The application scope primarily covers topical treatments, systemic drugs, and biologics, with end-users ranging from hospitals, pharmacies, online retailers, and dermatology clinics. Key growth factors include heightened awareness of skin health, increased healthcare expenditure, advancements in biotechnology, and a growing pipeline of innovative drugs such as monoclonal antibodies and JAK inhibitors. Recent opportunities emerge from expanding the use of biologics, which target inflammation pathways with high specificity, and the potential for personalized medicine, which tailors treatments based on genetic profiles. However, market growth is challenged by high drug development costs, regulatory hurdles, and the need for extensive clinical trials, coupled with competitive market dynamics and potential side effects associated with some treatments. To seize emerging opportunities, stakeholders should focus on investing in R&D that pushes for the development of more effective and safer biologics, exploring natural and alternative remedies, and leveraging digital therapeutics for monitoring and managing AD symptoms. Proactive engagement in collaborations and partnerships can facilitate knowledge transfer and innovative breakthroughs. Moreover, innovation could aim at creating more cost-effective formulations to broaden accessibility. The nature of the atopic dermatitis drugs market is highly competitive and research-intensive, characterized by constant evolution driven by scientific advancements and patient-centric demand, necessitating agile strategies to stay ahead in the market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Atopic Dermatitis Drugs Market

The Atopic Dermatitis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of atopic dermatitis
  • Growing prevalence of food allergies intensifying atopic dermatitis
  • Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
• Market Restraints
  • High cost of therapeutics
• Market Opportunities
  • Rising awareness regarding the availability of treatments for the disease
  • Growing access to treatment in various developing countries
• Market Challenges
  • Adverse effects associated with the use of medication

Porter's Five Forces: A Strategic Tool for Navigating the Atopic Dermatitis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Atopic Dermatitis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Atopic Dermatitis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Atopic Dermatitis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Atopic Dermatitis Drugs Market

A detailed market share analysis in the Atopic Dermatitis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Atopic Dermatitis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Atopic Dermatitis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Atopic Dermatitis Drugs Market

A strategic analysis of the Atopic Dermatitis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Atopic Dermatitis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma S.A., GlaxoSmithKline PLC, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Atopic Dermatitis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Biologics, Calcineurin Inhibitors, Corticosteroids, and Phosphodiesterases 4 Inhibitors.
• Based on Route of Administration, market is studied across Injectable ROA, Oral ROA, and Tropical ROA.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of atopic dermatitis
    • 5.1.1.2. Growing prevalence of food allergies intensifying atopic dermatitis
    • 5.1.1.3. Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising awareness regarding the availability of treatments for the disease
    • 5.1.3.2. Growing access to treatment in various developing countries
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with the use of medication
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Atopic Dermatitis Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Calcineurin Inhibitors
• 6.4. Corticosteroids
• 6.5. Phosphodiesterases 4 Inhibitors

7. Atopic Dermatitis Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable ROA
• 7.3. Oral ROA
• 7.4. Tropical ROA

8. Americas Atopic Dermatitis Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Atopic Dermatitis Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Atopic Dermatitis Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Bausch Health Companies Inc.
• 3. Bayer AG
• 4. Biofrontera AG
• 5. Bristol-Myers Squibb Company
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche Ltd.
• 8. Galderma S.A.
• 9. GlaxoSmithKline PLC
• 10. LEO Pharma A/S
• 11. Meda AB
• 12. Mylan N.V.
• 13. Novartis AG
• 14. Pfizer Inc.
• 15. Regeneron Pharmaceuticals, Inc
• 16. Sanofi S.A.
• 17. Teva Pharmaceutical Industries Ltd.